Diagnosis, clinical management and research of psychiatric disorders remain subjective -largely guided by historically developed categories which may not effectively capture underlying pathophysiological mechanisms of dysfunction. Here, we report a novel approach of identifying and validating distinct and biologically meaningful clinical phenotypes of bipolar disorders using both unsupervised and supervised machine learning techniques. First, neurocognitive data were analyzed using an unsupervised machine learning approach and two distinct clinical phenotypes identified namely; phenotype I and phenotype II. Second, diffusion weighted imaging scans were pre-processed using the tract-based spatial statistics (TBSS) method and 'skeletonized' white matter fractional anisotropy (FA) and mean diffusivity (MD) maps extracted. The 'skeletonized' white matter FA and MD maps were entered into the Elastic Net machine learning algorithm to distinguish individual subjects' phenotypic labels (e.g. phenotype I vs. phenotype II). This calculation was performed to ascertain whether the identified clinical phenotypes were biologically distinct. Original neurocognitive measurements distinguished individual subjects' phenotypic labels with 94% accuracy (sensitivity = 92%, specificity = 97%). TBSS derived FA and MD measurements predicted individual subjects' phenotypic labels with 76% and 65% accuracy respectively. In addition, individual subjects belonging to phenotypes I and II were distinguished from healthy controls with 57% and 92% accuracy respectively. Neurocognitive task variables identified as most relevant in distinguishing phenotypic labels included; Affective Go/No-Go (AGN), Cambridge Gambling Task (CGT) coupled with inferior fronto-occipital fasciculus and callosal white matter pathways. These results suggest that there may exist two biologically distinct clinical phenotypes in bipolar disorders which can be identified from healthy controls with high accuracy and at an individual subject level. We suggest a strong clinical utility of the proposed approach in defining and validating biologically meaningful and less heterogeneous clinical sub-phenotypes of major psychiatric disorders.
Diagnosis, clinical management and research of psychiatric disorders remain subjective -largely guided by historically developed categories which may not effectively capture underlying pathophysiological mechanisms of dysfunction. Here, we report a novel approach of identifying and validating distinct and biologically meaningful clinical phenotypes of bipolar disorders using both unsupervised and supervised machine learning techniques. First, neurocognitive data were analyzed using an unsupervised machine learning approach and two distinct clinical phenotypes identified namely; phenotype I and phenotype II. Second, diffusion weighted imaging scans were pre-processed using the tract-based spatial statistics (TBSS) method and 'skeletonized' white matter fractional anisotropy (FA) and mean diffusivity (MD) maps extracted. The 'skeletonized' white matter FA and MD maps were entered into the Elastic Net machine learning algorithm to distinguish individual subjects' phenotypic labels (e.g. phenotype I vs. phenotype II). This calculation was performed to ascertain whether the identified clinical phenotypes were biologically distinct. Original neurocognitive measurements distinguished individual subjects' phenotypic labels with 94% accuracy (sensitivity = 92%, specificity = 97%). TBSS derived FA and MD measurements predicted individual subjects' phenotypic labels with 76% and 65% accuracy respectively. In addition, individual subjects belonging to phenotypes I and II were distinguished from healthy controls with 57% and 92% accuracy respectively. Neurocognitive task variables identified as most relevant in distinguishing phenotypic labels included; Affective Go/No-Go (AGN), Cambridge Gambling Task (CGT) coupled with inferior fronto-occipital fasciculus and callosal white matter pathways. These results suggest that there may exist two biologically distinct clinical phenotypes in bipolar disorders which can be identified from healthy controls with high accuracy and at an individual subject level. We suggest a strong clinical utility of the proposed approach in defining and validating biologically meaningful and less heterogeneous clinical sub-phenotypes of major psychiatric disorders.
Introduction
Diagnosis and clinical management of psychiatric disorders largely rely on traditional symptom-based classification systems such as the diagnostic and statistical manual (DSM) and the international classification of disease (ICD). However, it has been suggested that these symptombased classification systems do not necessarily align with pathophysiological mechanisms of dysfunction Frangou, 2013; Hickie et al., 2013; Insel et al., 2010; Insel & Cuthbert, 2015; Morris & Cuthbert, 2012) . Furthermore, the current classification systems consider psychiatric disorders as unique phenotypic entities -while there is evidence of symptom overlap and diagnostic heterogeneity within disorders (Wardenaar & de Jonge, 2013) . The current impasse has undoubtedly slowed down development of objective diagnostic markers of disease and effective treatments. To address this issue the National Institute of Mental Health (NIMH) has recently proposed the Research Domain Criteria (RDoC) initiative which is aimed at "developing, for research purposes, new ways of classifying mental disorders based on dimensions of observable behavior and neurobiological measures" (National Institute of Mental Health, 2008) . Notably, the RDoC framework offers a promising alternative to standard classification systems as it views psychiatric disorders from a multidimensional viewpoint and integrates molecular, behavioral, motivational and cognitive data (Insel, 2014) . To date, few studies have adopted the RDoC classification system to describe the clinical status and neurocognitive functioning of patients with neuropsychiatric disorders.
In line with this goal, the two main objectives of this study were; first, to determine whether we can identify distinct clinical phenotypes based on a composite representation of neurocognitive data. Second, investigate whether neuroimaging measurements acquired from diffusion weighted scans are predictive of identified phenotypes at an individual subject level and with above chance level accuracy. Notably, in this study we refer to disease phenotypes as subgroups or subclassifications of patient groups with unique patterns of neurocognitive functioning. As a first step, this approach was applied on a sample of patients with bipolar disorders and validated against matched healthy controls.
Bipolar disorder (BD) is a common psychiatric disorder characterized by mania or hypomania, mostly alternating with depression and ranked among top 20 causes of disability worldwide (Hirschfeld & Vornik, 2005; Murray et al., 2013; Rajkowska et al., 2001) . BD is associated with a high socio-economic burden including suicidality, substance abuse and comorbidity with other disorders (Galvez et al., 2014; Hirschfeld & Vornik, 2005; Müller-Oerlinghausen et al., 2002) . Clinically, BD is categorized into two main subtypes; 1) bipolar I disorder (BD I) -characterized by one or more manic or mixed episodes, accompanied by one or multiple depressive episodes (Association, 2000; Müller-Oerlinghausen et al., 2002) . 2) Bipolar II disorder (BD II) -characterized by one or more hypomanic episodes with recurrent depressive episodes (Association, 2000; Müller-Oerlinghausen et al., 2002) . Noticeably, these clinical subtypes are based on observed and potentially heterogeneous 'signs and symptoms' as opposed to measureable neurobiological or behavioral characteristics. Consequently, the main motivation of this study was not to investigate neurobiological differences across subtypes of BD but to investigate distinct neurobiologically relevant phenotypes within the entire bipolar disorder spectrum. Markedly, identifying neurobiologically distinct phenotypes may lead to development of more effective, bettertargeted treatments and most importantly personalized or individualized treatments. Indeed, this is also inline with the recently proposed P4 (predictive, preventive, personalized and participatory) medicine framework in investigating major medical conditions (Hood & Friend, 2011) .
Multiple neurocognition studies have reported impaired cognition in BD patients as compared to healthy individuals. For example, a recent meta-analysis summarizing 42 studies observed significant impairments in BD patients across multiple domains such as attention, working memory, verbal/non-verbal memory, visuospatial function, psychomotor speed, language and executive function (Kurtz & Gerraty, 2009) . Most recently, several studies have successfully identified unique neurocognitive subgroups using data-driven machine learning algorithms (Brodersen et al., 2014; Burdick et al., 2014; Fair et al., 2012; Heinrichs & Awad, 1993; LEE et al., 2014) . Distinctively, a recent longitudinal study reported a data-driven approach able to identify neurocognition subgroups which proved to be useful in predicting longitudinal functional outcomes (Hermens et al., 2011) . However, while these studies have undoubtedly offered significant insights on unique and objective phenotypes of psychiatric disorders -the association between these data-driven phenotypes and other neurobiological measurements (e.g. white matter tissue diffusivity) remains largely unexplored. Furthermore, a significant advance would be to demonstrate that neuroimaging measurements are highly predictive of identified disease phenotypes albeit at an individual subject level. Notably though, there is active research work in this area (Brodersen et al., 2014; Geisler et al., 2015; Karalunas et al., 2014) .
Multiple studies have recently demonstrated the utility of machine learning or pattern recognition algorithms in making clinically relevant predictions at an individual subject level (Johnston et al., 2014; Lavagnino et al., 2015; Mwangi et al., 2012a; Mwangi et al., 2012b; Mwangi et al., 2014b; Rocha-Rego et al., 2014) . Specifically, previous studies have attempted to discriminate DSM defined categories from matched healthy controls using neuroanatomical scans (Mwangi et al., 2012a; Oliveira et al., 2013; Schnack et al., 2014) . However, while these algorithms have been received within the neuropsychiatric community with great optimism, a major criticism has been that these algorithms are ordinarily 'trained' to categorize patients based on symptom-based DSM defined categories -an assumption which may lead to circularity (Mwangi et al., 2014a; Savitz et al., 2013) . In this study though, we somewhat circumvent this limitation by first; identifying distinct behavioral phenotypes using neurocognitive data and an unsupervised machine-learning technique. Second, using diffusion weighted neuroimaging scan data such as mean diffusivity (MD) and fractional anisotropy (FA) we 'train' a machine learning algorithm to distinguish individual subjects among clinical phenotypes as well as healthy controls. Importantly, to allow inter-subject comparisons diffusion weighted imaging FA and MD maps were pre-processed using the tract-based spatial statistics (TBSS) method (Smith et al., 2006) . This entailed spatial normalization of subjects' FA and MD volumes into a standardized template coupled with a 'tract skeletonization' process to account for any residual misalignments and resulting FA and MD volumes used in the machine learning analyses and phenotype validation.
Materials and methods

Subjects
This study was approved by the local Institutional Review Board (IRB) at The University of North Carolina at Chapel Hill. Study participants included 70 patients with DSM-IV diagnosis of BD as shown in Table 1 . A diagnosis of BD in patients was established through administration of the structured clinical interview for the diagnostic and statistical manual of mental disorders axis I (SCID I) (First et al., 2012) . Subjects were excluded if they met criteria for substance abuse or BPD -bipolar disorder, SD -standard deviation, YMRS -Young Mania Rating Scale, HDRS -Hamilton Depression Rating Scale, MADRS -Montgomery-Asberg Depression Scale, SES -social economic status, PTSD -post-traumatic stress disorder, OCD -obsessive compulsive disorder, GAD -generalized anxiety disorder.
dependence in the last 6 months preceding their participation in the study. Additional exclusion criteria were positive pregnancy test, neurological disorders, head injury with loss of consciousness and family history of hereditary neurologic disorders. Participants' affective state was assessed with the Hamilton Depression Rating Scale (HDRS) -21 items and the Young Mania Rating Scale (YMRS) (Young et al., 1978) , and the Montgomery-Asberg Depression Scale (MADRS) (Davidson et al., 1986) .
Neurocognitive data
Participants performed the computerized Cambridge Neurocognitive Test Automated Battery (CANTAB -http://www.cantab.com). This cognitive battery was chosen based on the established sensitivity to cognitive impairments in psychiatric disorders (Sweeney et al., 2000) . Participants completed tests evaluating visuomotor speed (Choice Reaction Time -CRT, Motor Screening -MOT), selective and continuous visual attention (Match to Sample Visual Search -MTS, Rapid Visual Processing -RVP), working memory and planning (Intra/ Extradimensional Set Shift -IED, Spatial Span task -SSP, Spatial Recognition Memory -SRM), and cognitive control (Affective Go/No-Go -AGN, Cambridge Gambling Task -CGT). These neurocognitive tasks are briefly described in Table 2 and a detailed description is also given elsewhere (Robbins et al., 1994) .
These cognitive tasks assess domains of the NIMH RDoC framework such as arousal, cognitive control, declarative memory, social communication and valence system. Therefore, based on the preliminary description of the RDoC cognitive constructs provided elsewhere (http://www. nimh.nih.gov/research-priorities/rdoc/rdoc-constructs.shtml) we mapped the CANTAB tasks onto the RDoC construct in the following manner:
1. Arousal: includes measures of basic motor and cognitive processing speed such as the RTs in the CRT, MTS and MOT tasks. A conceptual diagram of our analytical approach and mapping of the CANTAB tasks onto the RDoC framework are presented in Fig. 1 and Table 2 .
Neuroimaging data acquisition and pre-processing Diffusion weighted imaging (DWI) scans were acquired using a 3.0 T Siemens Allegra scanner using a spin echo-planar imaging (EPI) protocol with the following acquisition parameters. Repetition time (TR) = 9200 ms, echo time = 79 ms, slice thickness = 2 mm, voxel size = 2 mm, image matrix = 104 × 128 with 21 diffusion encoding directions, b-value = 1000 s/mm 2 and one non-diffusion weighted volume (b = 0). All DWI scans were inspected visually to rule out any gross artifacts (e.g. ghosting). Scans were pre-processed using the FMRIB software package (FSL) version 5.0.7 (Smith, 2002) through the following steps. 1) Head motion and 'eddy currents' correction using FSL's 'eddy_correct' routine. 2) Removal of non-brain tissue (e.g. skull) using the brain extraction tool (BET). 3) Calculation and diffusion tensor fitting at every voxel as detailed elsewhere (Johansen-Berg & Behrens, 2013) . 4) Lastly, estimation of fractional anisotropy (FA) and mean diffusivity (MD) values was performed resulting into individual subjects' FA and MD image volumes. To allow inter-subject statistical comparisons, scans were pre-processed using the tract-based spatial statistics (TBSS) (Smith et al., 2006) routine as follows. FA volumes were spatially aligned into a standard template available with FSL (FMRIB58_FA) through a non-linear registration routine (FNIRT) (Smith et al., 2006) . Spatially aligned FA volumes were averaged to create a group average FA volume which was input into a 'tract skeletonization' routine as implemented in FSL (Smith et al., 2006) . The tract sekeleton represents white matter tracts as single lines going through the center of the tract -a process often used to account for any residual misalignments due to the spatial normalization process (Johansen-Berg & Behrens, 2013). Lastly, individual subjects' spatially normalized FA images were 'projected' onto the mean FA skeleton and thresholded using mean FA = 0.2 to exclude voxels which are potentially within gray matter or cerebral spinal fluid (CSF) and therefore avoid partial voluming.
The spatial normalization and a subsequent skeletonization calculation were also applied to MD volumes as described elsewhere (Smith et al., 2006) . This process resulted in FA and MD variables or feature vector of dimension 1 × 113,084 and subsequently used in the ensuing machine learning analyses.
Identification of data-driven phenotypes using neurocognitive data 90 cognitive scores of the CANTAB (see Supplementary material, Table S1 ) were normalized by subtracting the mean and dividing with standard deviation (z-score) and entered into principal component analysis (PCA) (Jolliffe, 2005; Mwangi et al., 2014c) for data dimensionality reduction. Resulting principal components were entered into the kmeans clustering algorithm (Hartigan & Wong, 1979) for clustering and phenotype identification. However, this approach required identification of two parameters. 1) Optimal number of principal components. 2) Ideal number of k-means clusters. These two data-driven parameters were identified using a 'grid-search' procedure which was optimized to maximize the average silhouette width value (Rousseeuw, 1987) . Silhouette width value (SWV) is a statistical measure used to quantify similarity of a data point to other points within its own cluster as compared to data points in other clusters. SWV falls between −1 and 1, with a value of 1 signifying most optimal number of clusters as further described in the Supplementary materials and elsewhere (Mwangi et al., 2014a) . Lastly, resulting low-dimensional data from PCA were visualized using the t-distributed stochastic neighbor embedding (t-SNE) technique (Van der Maaten & Hinton, 2008) . t-SNE is a data visualization technique used to embed high dimensional data (N3) into a low dimensional space (e.g. 2D) for visualization purposes (Mwangi et al., 2014a; Plis et al., 2014) . The phenotype identification process is conceptually summarized in Fig. 1 . A summary of BD patients identified in two phenotypes (phenotype I and phenotype II) with matched healthy controls is shown in Table 3 .
Phenotype validation using neurocognitive data.
Neurocognitive scores (without PCA data reduction) were input into the least absolute shrinkage and selection operator (LASSO) algorithm (Tibshirani, 1996 (Tibshirani, , 2011a which was 'trained' to identify individual subjects' phenotypic labels and prediction accuracy (specificity and sensitivity) calculated. Specifically, we assumed a two group classification problem (e.g. phenotype I vs. phenotype II) with predictor variables or features (neurocognitive data) represented as, x ij where i = 1 , 2 , … N represents number of subjects and j = 1 , 2 , … P represents number of predictor variables or features. In addition, y i represents corresponding target labels (1 -phenotype I, 2 -phenotype II). As a result, the LASSO algorithm was used to compute a set of coefficients (β) by minimizing the following objective function (Tibshirani, 1996; Tibshirani, 2011b) .
The algorithm parameter (λ) which is used to encourage algorithm sparsity -translating into fewer coefficients with non-zero weights was selected using a 10-fold cross-validation approach. This parameter was selected using training data only to avoid circularity also known as double dipping (Kriegeskorte et al., 2009; Mwangi et al., 2014c) . The LASSO objective function was optimized using the coordinate descent algorithm through a MATLAB (The Mathworks, Inc.) toolbox provided by Friedman et al. (2010) . Lastly, a generalized linear model was used to estimate the probability of an individual subject belonging to either phenotype I or phenotype II, given raw neurocognitive scores and the identified LASSO coefficients (β). In addition, the LASSO algorithm was also 'trained' to distinguish individual phenotype I or phenotype II patients from healthy controls. In each comparison (e.g. phenotype I vs. healthy controls) a leave-one-out cross-validation (LOOCV) approach was used to 'train' and 'test' the model while the penalty parameter (λ) was selected using a 10-fold cross-validation with training data only. LOOCV involves 'training' an algorithm with all subjects but one while the 'left out' subject is used for algorithm testing Fig. 1 . A flow diagram illustrating the 'top-down' conceptual approach used in this study. A) Phenotypes were identified using CANTAB neurocognitive scores through data dimensionality reduction and clustering using the principal component analysis and k-means clustering techniques. B) Phenotypes were validated using raw neurocognitive scores (without data dimensionality) and neuroimaging measurements (fractional anisotropy and mean diffusivity). Supervised machine learning techniques -LASSO and Elastic Net were 'trained' to predict individual subjects' phenotypic labels using neurocognitive scores or neuroimaging measurements. The supervised model was 'trained' and 'tested' using a leave-one-out cross-validation process. (Johnston et al., 2013) . This procedure is repeated until all subjects are 'left out' for algorithm testing at least once and prediction accuracy, sensitivity, and specificity are estimated. Clinical and demographic characteristics of BD patients included in both phenotype I and phenotype II with a matched healthy control group are summarized in Table 3 .
Phenotype validation using tract-based spatial statistics diffusion weighted imaging data
To establish whether the identified behavioral phenotypes were neurobiologically distinct, we examined whether diffusion weighted FA and MD volumes pre-processed using tract-based spatial statistics (TBSS) can distinguish individual patients in phenotype I from those in phenotype II as well as healthy controls. Specifically, the TBSS pre-processed FA and MD volumes were entered into a two-group (e.g. phenotype I vs. phenotype II) Elastic Net machine learning algorithm (Zou & Hastie, 2005 ) -which was 'trained' to predict individual subjects' phenotypic labels and resulting model prediction accuracy, specificity and sensitivity calculated. The Elastic Net algorithm follows a similar formulation as the LASSO albeit with an additional penalty term to encourage variable grouping and a more stable solution (Mwangi et al., 2014c; Ogutu et al., 2012; Zou & Hastie, 2005) . The additional penalty term in the Elastic Net translates into the following objective function (Zou & Hastie, 2005) 
Similar to above, x ij stands for predictor variables (e.g. TBSS derived FA or MD) while y i represents corresponding target labels (e.g. 1 -phenotype I and 2 -phenotype II), where i =1,2, … N represents observations or subjects and j =1,2, … P represents number of predictor variables (features). The Elastic Net algorithm parameters (λ 1 and λ 2 ) were selected using a 10-fold grid-search process using training data only and the algorithm's objective function solved through the coordinate descent algorithm using a MATLAB (The Mathworks, Inc.) toolbox provided by Friedman et al. (2010) . Importantly, the Elastic Net algorithm was used in the neuroimaging phenotype validation step as unlike the LASSO where number of relevant predictor variables (non-zero coefficients) may not exceed number of observations, the Elastic Net allows relevant variables to exceed number of observations (Zou & Hastie, 2005) and therefore more suitable in visualizing relevant group-level statistical maps. Similar to above, a generalized linear model was used to estimate a probability of an individual subject belonging to phenotype I or phenotype II patient groups given TBSS preprocessed FA and MD features. In addition, the Elastic Net algorithm was also 'trained' to distinguish individual phenotype I or phenotype II patients from healthy controls. In each comparison (e.g. phenotype I vs. healthy controls) a LOOCV approach was used to establish prediction accuracy while algorithm parameters were selected using a 10-fold cross-validation approach using training data only as shown in Fig. 2 . Importantly, a 'consensus group-level map' highlighting FA or MD differences among groups (e.g. phenotype I vs. phenotype II) was generated by identifying features identified by the algorithm as 'relevant' -by the virtue of having a non-zero model coefficients across all LOOCV iterations. A 'consensus map' approach has previously been used to summarize group-level differences in machine learning studies (Dosenbach et al., 2010; Mwangi et al., 2013) . Lastly, prediction accuracy, sensitivity and specificity in identifying patients from both phenotypes using FA and MD features were summarized and reported. A similar calculation was performed between the healthy control and patient phenotypic groups. Table 1 summarizes the sociodemographic and clinical details of BD patients used in the phenotype identification process. The unsupervised machine learning approach identified two phenotypes as shown in Fig. 1 . Detailed sociodemographic and clinical characteristics of both phenotypes are shown in Table 3 . The optimal number of principal components in PCA was selected using a 'grid-search' procedure by maximizing the average silhouette width value as shown in Fig. 3 . The most optimal silhouette width value was 0.74. Raw CANTAB measurements (without PCA data reduction) predicted individual subjects' phenotypic labels with 94% accuracy, 97% specificity, 92% sensitivity, 0.945 area under receiver operating characteristic curve and chisquare (p b 0.005) as shown in Fig. 4 . As illustrated in Table 4 the CANTAB tasks identified by the LASSO algorithm as most relevant in distinguishing phenotype I and phenotype II subjects included the AGN (relevant variables included the mean RT to correct trials across non-shift blocks, in particular those starting with positive stimuli, and during shift blocks starting with negative stimuli, and the number of commission errors during non-shift blocks starting with neutral stimuli), the CGT (quality of decision making), the IED (accuracy on the extradimensional component) and CRT (general alertness and motor speed). Table 5 summarizes prediction results in distinguishing individual patients in phenotype I from those in phenotype II using neurocognition and diffusion weighted measurements (FA and MD). Specifically, Elastic Net algorithm 'trained' using FA data distinguished both phenotypes with 75.9% accuracy. In addition, individual phenotype II patients were distinguished from healthy controls with 92% accuracy as shown in Table 5 . The most relevant anatomical regions in distinguishing phenotype I and phenotype II patients included frontal white matter tracts such as; inferior frontal-occipital fasciculus (IFOF) and the minor forceps of the corpus callosum. In particular, phenotype II showed reduced FA and increased MD values in a significant cluster within the IFOF as compared to phenotype I patients and healthy controls as shown in Fig. 5 .
Results
Discussion
We have presented a proof-of-concept study investigating the utility of an unsupervised data-driven machine learning approach to identify biologically distinct and less heterogeneous phenotypes in bipolar disorders. Most importantly, our approach utilizes neurocognitive measurements to identify unique phenotypes which are validated using neuroanatomical markers. The most compelling finding of this study is the identification of two unique phenotypes (phenotype I, phenotype II) which did not overlap with DSM-IV derived categories (BD I, BD II and BD-NOS). Notably, phenotypes I and II display distinct cognitive profiles on the cognitive control, social communication and arousal RDoC constructs. Markedly, neuroimaging measurements of microstructural white matter diffusivity successfully identified individual subjects from both phenotypes with high accuracy. In addition, individualized prediction distinguished patients from both phenotypes from healthy controls -in particular phenotype II patients.
Most relevant neurocognitive and neuroanatomical measurements
The most relevant CANTAB measurements in separating the two phenotypes included measures of reaction time in the AGN task, response accuracy in the ID/ED, and quality of decision making during the CGT task. Importantly, we report two key observations and characteristics of both phenotypes from the CANTAB measurements. First, phenotype I patients exhibited reduced response accuracy during the AGN and IED tasks and slow decision making during the CGT task. Second, phenotype II patients exhibited slower reaction time in the AGN and CRT tasks but their decision-making approach was more efficient than that of phenotype I patients. Therefore, it could be argued that phenotype II patients completed the AGN and CGT tasks in a strategic manner, by trading speed for accuracy. The slow reaction times in both the AGN and CRT tasks may also be consistent with psychomotor slowing. Notably, in the AGN task individuals with phenotype I made a greater number of commission errors in response to positive and neutral stimuli but not to negative stimuli when compared to individuals with phenotype I. This pattern of responses is in line with concept of "negative affective bias", a well-established feature of mood disorders including bipolar disorders (Bauer et al., 2015; Gotlib et al., 2005) . Negative affective bias is defined by the inability to disengage from processing negative stimuli even after they disappear. This inability impairs the Fig. 2. Flow diagram showing the leave-one-out cross-validation process used with the Elastic Net algorithm in predicting subjects' phenotypic labels. Algorithm regularization parameters were selected using a 10-fold grid-search process using training data only to avoid circularity or double dipping. Fig. 3 . A) Grid-search plot illustrating a search for optimal number of principal components and k-means number of clusters that lead to a high silhouette width value. The grid-search process selected 4 components accounting for 43.09% variance and 2 clusters with a silhouette width value of 0.735. B) 2-Dimensional (2D) visualization of phenotype I and phenotype II patient groups. Low dimensional 2D points were generated using the t-distributed stochastic neighbor embedding (t-SNE) technique by mapping the most relevant principal components (leading to a high silhouette width value) from a high-dimensional (4D) into a lower visually plausible 2D space. Importantly, the two phenotypes did not overlap with DSM-IV related categories (BP I, II and BP-NOS). Notably, t-SNE units are arbitrary and they only depict subjects' similarities based on Euclidean distances.
processing of subsequent stimuli and could explain the reduced accuracy in processing positive and neutral stimuli (Singhal et al., 2012) , as observed in the current study. Previous studies found that verbal memory, psychomotor speed, executive functioning, and to a less extent visual memory and attention, are greatly impaired in BPD patients (Bora et al., 2009; Cavanagh et al., 2002; Glahn et al., 2007; Lopes & Fernandes, 2012; Martínez-Arán et al., 2004; Quraishi & Frangou, 2002; Sapin et al., 1987; Zubieta et al., 2001) . In a recent study, patients with BD type I displayed a preservative and risky behavior in the CGT (Linke et al., 2013) . Notably, relatives of BD patients displayed a similar cognitive performance, which along with our present findings; indicate that the performance in the CGT task may be a potential marker of disease susceptibility. However, other studies examining executive functions in BD are more controversial as they suggest a possible effect of mood phase on cognitive functioning. For instance, Clark and colleagues found that euthymic BD encountered set-shifting difficulties during the IED task (Clark et al., 1999) , while another study found that the performance of a bipolar sample in a depressed/mixed state was comparable to that of healthy volunteers (Sweeney et al., 2000) . It is noteworthy that in the current study, phenotype I and phenotype II patients were comparable in regard to subjects' current level of mood symptoms. Therefore, differences in performance in the CANTAB tasks are unlikely to be related to the mood of the participants. Additionally, the reported executive function impairment (e.g. slow reaction times and errors in the AGN task) in both phenotypes is consistent with previous evidence of structural and functional abnormalities in anatomical regions responsible for executive control in pediatric and adult populations with BD (Brambilla et al., 2002; Hajek et al., 2005; Houenou et al., 2011; Lim et al., 2013; Sassi et al., 2004; Soares & Mann, 1997) . Compared to individuals with phenotype I, those with phenotype II displayed slowed reaction times in the AGN and CRT tasks. Notably the quality of the decision making (e.g. gambling on stimuli with a more likely outcome) was higher in phenotype II than in phenotype I. Phenotype I is characterized by an overall higher number of commission errors in the AGN and ID/IED tasks, and slowed decision making in the CGT task.
In terms of imaging results, white matter diffusivity values within the frontal white matter tracts were most relevant in distinguishing individual patients from both phenotypes. As shown in Table 6 , the most Fig. 4 . A) Confusion matrix and ROC curve generated from a LASSO algorithm which was trained using 'raw' neurocognitive tasks scores (see Table 2 ) to predict individual subject phenotypic labels. The model predicted individual subject phenotypic labels with 94% accuracy (sensitivity = 92%, specificity = 97%) and area under ROC curve (AUC) = 0.9449. B) Confusion matrix and ROC curve generated from a Elastic Net algorithm which was trained using whole brain fractional anisotropy values to predict individual subject phenotypic labels. The model predicted individual subject phenotypic labels with 76% accuracy (sensitivity = 76%, specificity = 76%) and area under ROC curve (AUC) = 0.7593.
Table 4
Cognitive task scores most relevant in distinguishing phenotype I from phenotype II patients using LASSO. relevant clusters were within the inferior fronto-occipital fasciculus (IFOF) and the minor forceps of the corpus callosum. In particular, phenotype II patients showed reduced FA values and increased MD values within the IFOF as compared to phenotype I patients and healthy controls. The IFOF is a white matter pathway that connects the posterior or superior temporal regions with the dorsolateral prefrontal cortex (McCrea, 2008) . Although the IFOF connects the frontal temporal and occipital lobes, it's main functions are still not very well understood although there is evidence that this white matter pathway connects the prefrontal cortex and auditory as well as visual association cortex and associated with functions such as semantic processing and attentional set-shifting ability (Kvickström et al., 2011) . A recent meta-analysis reported reduced FA in the IFOF of bipolar disorder patients as compared to healthy controls (Vederine et al., 2011) . However, in the current study, we observed reduced FA and increased MD in the IFOF of phenotype II patients as compared to healthy controls and not in phenotype I patients. Other white matter anatomical regions most relevant in distinguishing phenotype I from phenotype II patients included; isthmus of the corpus callosum, mid colossal pathways, anterior forceps of corpus callosum as well as the cingulum. In summary, phenotype II patients reported reduced FA and increased MD values within the IFOF white-matter tract and longer reaction time in the AGN cognitive task. The current application of the RDoC approach is to be viewed as a first step in parsing out heterogeneity in complex psychiatric disorders. However, although the RDoC framework is increasingly being used in clinical research, to the best of our knowledge this is among the first studies that have used the RDoC cognitive constructs in combination with neuroimaging measures to identify and validate biologically distinct disease phenotypes. Consequently, given the lack of clear guidelines to "translate" classical neuropsychological measures into the RDoC framework, this approach is challenging as it relies on the subjective evaluation of the definition of each cognitive domains, but certainly constitutes a starting point to improve understanding of the RDoC dimensions.
Limitations
Potential limitations of this study should be noted. First, the study sample size was small and therefore this approach will need to be validated using a larger sample size. However, the generalization ability of the supervised machine learning algorithms using both neurocognitive data and diffusion weighted neuroimaging scan data were significant (chi-square p b 0.05). This indicates that the sample size may have been adequate to identify biologically distinct phenotypes. Our sample did not include other DSM related categories (e.g. major depression or schizophrenia) and future work will focus on extending the sample in a 'dimensional' approach to include other psychiatric syndromes and spectrums (e.g. depression, psychosis) as also hypothesized elsewhere (Insel & Cuthbert, 2015; Mwangi et al., 2014a; Stephan et al., 2015) . Markedly, future work will also focus on examining the utility of multi-class or multinomial classification methods in identifying subjects from all groups (e.g. phenotype I vs. phenotype II vs. healthy controls) as well as validating identified phenotypes using other biological markers such as genetics.
Conclusion
We highlight three notable observations from this proof-of-concept study. First, multivariate patterns of neurocognitive measurements are potentially useful in patient stratification and unearthing distinct or monolithic phenotypes in heterogeneous patient populations. Second, neuroimaging measurements are potential validators and predictors of phenotypic groups identified using behavioral data. Third, machine learning predictive classification techniques (e.g. LASSO, Elastic Net) give a strong indication that identified phenotypes are biologically relevant and may be useful clinically. Data-driven and biologically relevant disease phenotypes identified using this approach will give the psychiatric research community a unique opportunity to identify objective and biologically relevant disease categories. Markedly, if we are to determine objective and clinically meaningful phenotypic bio-signatures which can be identified through quick and hazard free biological tests -this will lead to improved patient care and better targeted therapeutic interventions.
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